| Hipoglucemiantes orales para el tratamiento de diabetes mellitus tipo 2: uso y regulación en México NS Rodríguez-Rivera, P Cuautle-Rodríguez, JA Molina-Guarneros Revista del Hospital Juárez de México 84 (4), 203-211, 2017 | 35 | 2017 |
| Activated Notch1 is a stronger astrocytic stimulus than leukemia inhibitory factor for rat neural stem cells NS Rodríguez-Rivera, A Molina-Hernández, E Sánchez-Cruz, ... International Journal of Developmental Biology 53 (7), 947-953, 2009 | 17 | 2009 |
| Identification of genetic variants in pharmacogenetic genes associated with type 2 diabetes in a Mexican-Mestizo population NS Rodríguez-Rivera, P Cuautle-Rodríguez, F Castillo-Nájera, ... Biomedical Reports 7 (1), 21-28, 2017 | 11 | 2017 |
| Frequency of CYP2C9 (* 2,* 3 and IVS8‑109A> T) allelic variants, and their clinical implications, among Mexican patients with diabetes mellitus type 2 undergoing treatment with … P Cuautle‑Rodríguez, N Rodríguez‑Rivera, F De Andrés, ... Biomedical reports 10 (5), 283-295, 2019 | 6 | 2019 |
| Oral hypoglycemic agents for the treatment of diabetes mellitus type 2: use and regulation in Mexico NS Rodríguez-Rivera, P Cuautle-Rodríguez, JA Molina-Guarneros Revista del Hospital Juárez de México 84 (4), 203-211, 2017 | 5 | 2017 |
| Pharmacogenetics of metformin transporters suggests no association with therapeutic inefficacy among diabetes type 2 Mexican patients A Ortega-Ayala, NS Rodríguez-Rivera, F Andrés, A LLerena, ... Pharmaceuticals 15 (7), 774, 2022 | 4 | 2022 |
| Exploring the Pathophysiology of ATP-Dependent Potassium Channels in Insulin Resistance NS Rodríguez-Rivera, D Barrera-Oviedo International Journal of Molecular Sciences 25 (7), 4079, 2024 | | 2024 |
| Polimorfismos de un solo nucleótido asociados con falla secundaria a sulfonilureas en pacientes con diabetes tipo 2: revisión documental MV Ayala-Martínez, NS Rodríguez-Rivera Farmacología 1 (1), 4, 2024 | | 2024 |
| Pharmacogenetics of Allelic Variants of CYP2C9 and Clinical Implications among Mexican Patients with Diabetes Mellitus Type 2 Undergoing Treatment with Glibenclamide and Metformin PC Rodríguez, NS Rodríguez-Rivera, FA Segura, A LLerena, ... BP International, 2023 | | 2023 |
| E23K (KCNJ11), and R1273R (ABCC8) polymorphism frequency in diabetes mellitus type 2 patients: glycemic control association in patients undergoing oral hypoglycemic treatment NS Rodríguez-Rivera, P Cuautle-Rodríguez, MG Ortiz-López, ... Revista del Hospital Juárez de México 86 (1), 17-25, 2019 | | 2019 |
| Frecuencia de los polimorfismos E23K (KCNJ11) y R1273R (ABCC8) en pacientes con diabetes mellitus tipo 2: asociación del control glucémico en pacientes tratados con … NS Rodríguez-Rivera, P Cuautle-Rodríguez, MG Ortiz-López, ... Revista del Hospital Juárez de México 86 (1), 17-25, 2019 | | 2019 |
| Polimorfismos de CYP P450 asociados a enfermedades y su valor como biomarcadores P CUAUTLE-RODRÍGUEZ, NS RODRÍGUEZ-RIVERA, E PÉREZ-SILVA, ... | | 2017 |
| Lack of Therapeutic Efficacy on Type 2 Diabetic Patients Treated with Glibenclamide and Metformin in Mexico City M Ramos-Coss, N Rodriguez-Rivera, JA Molina-Guarneros, ... PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 22, 488-489, 2013 | | 2013 |
| WITHDRAWN: Notch activation is a more robust gliogenic inductor than leukemia inhibitory factor in rat brain cortex neural stem cells I Velasco, N Rodríguez-Rivera Developmental Biology, 2007 | | 2007 |
| Notch activation is a more robust gliogenic inductor than leukemia inhibitory factor in rat brain cortex neural stem cells N Rodríguez-Rivera, I Velasco Developmental Biology 1 (306), 394, 2007 | | 2007 |
MOLINA-GUARNEROS JUNAMDirección de correo verificada de unam.mx
